Terminal β-galactose-containing glycan receptor

Terminal β-galactose-containing glycan receptors are a diverse class of cell-surface carbohydrates, including glycoproteins and glycolipids, characterized by a galactose residue in a β-linkage at the non-reducing terminus. These glycans serve as essential recognition motifs for endogenous lectins, particularly the galectin family, which play pivotal roles in cell-cell adhesion, immune cell activation, and apoptosis (Cummings et al., 2017). In pathological contexts, these terminal galactose residues are frequently exploited as attachment receptors by various pathogens, such as rotaviruses and certain bacterial species, to facilitate host cell invasion (Baker et al., 2012). Furthermore, aberrant expression or branching of these glycans is a hallmark of many cancers, where they facilitate metastasis by interacting with galectins in the tumor microenvironment (Thijssen et al., 2015). Therapeutic interventions targeting this system primarily involve galectin inhibitors, such as Belapectin, which competitively bind to the carbohydrate-recognition domain of galectins to prevent their interaction with these terminal galactose residues (Traber et al., 2013). These receptors are currently being investigated as targets for treating chronic fibrotic diseases, inflammatory disorders, and various malignancies. The specificity of these interactions is often determined by the underlying glycan structure and the specific galectin involved, making them complex but promising therapeutic targets. Clinical trials are ongoing to evaluate the efficacy of blocking these glycan-lectin interactions in conditions like non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis.

Other names

β-galactoside-containing glycansGalactose-terminated glycoconjugatesTerminal β-galactosyl glycansGal-terminated glycansβ-galactoside receptors

Competitive inhibition of lectin binding to terminal β-galactose residues, blocking downstream signaling or pathogen entry.